dr. siddiqi on rationale for the transcend cll 004 trial in cll/sll
Published 4 years ago • 130 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
7:52
dr. siddiqi on liso-cel in the transcend cll 004 study
-
1:36
dr. siddiqi on the results of the transcend cll 004 trial
-
2:19
dr. siddiqi on the safety profile of liso-cel in the transcend cll 004 trial
-
0:34
copy of dr. siddiqi on the safety profile of liso-cel in the transcend cll 004 trial
-
1:12
primary analysis of transcend-cll-004: liso-cel in r/r cll
-
3:17
transcend-cll-004 study update: safety and efficacy of liso-cel in r/r cll
-
1:21
dr. siddiqi on car t-cell therapy in relapsed/refractory cll/sll
-
4:00
the transcend-cll-004 study: jcar017
-
3:09
liso-cel induces rapid umrd: transcend-cll-004 update
-
3:56
transcend-cll-004: liso-cel in cll
-
3:34
transcend-cll-004: pivotal in the fda approval of liso-cel for r/r cll
-
4:20
extended follow-up of the transcend-cll-004 monotherapy cohort
-
28:25
dr tanya siddiqi - combination therapies in lymphoma and cll
-
1:07
dr. siddiqi on the cll14 trial results in cll
-
1:29
transcend-cll-04: 18-month follow-up of liso-cel for r/r cll
-
3:12
liso-cel in r/r cll: 24-month follow-up of transcend-cll-004
-
6:19
lisocabtagene maraleucel is efficacious at treating r/r cll/sll
-
1:12
dr. mato on immunotherapy options in cll
-
1:54
dr. fakhri on selecting the optimal treatment in cll